David Johnson, MD
Gastroenterology · Coeur D Alene, IDNPI 1124312376
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by AbbVie at 46.4% of the total. 2025 is the largest year on record at $84,581, more than ten times the $8,246 reported in 2019. Among gastroenterology clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 422 payments — averaging $449.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$88K
- Exact Sciences$79K
- Pfizer$17K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Janssen Scientific Affairs, LLC$876
- Bristol Myers Squibb$759
- plus $2K from 17 others
What the payments were for
- Consulting fees$43,47423%
- Speaking & faculty fees$110,92258%
- Travel & lodging$25,51913%
- Food & beverage$9,7925%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 140 | $88,085 |
| Exact Sciences | 133 | $78,958 |
| Pfizer | 43 | $17,452 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $1,522 |
| Janssen Scientific Affairs, LLC | 8 | $876 |
| Bristol Myers Squibb | 9 | $759 |
| Johnson & Johnson | 22 | $702 |
| Boston Scientific | 5 | $318 |
| Lilly USA, LLC | 4 | $242 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $183 |
| Regeneron Healthcare Solutions, Inc. | 7 | $135 |
| Intercept Pharmaceuticals, Inc. | 1 | $125 |
| Sanofi | 6 | $124 |
| Braintree Laboratories, Inc. | 5 | $89 |
| Merck | 3 | $51 |
| Gilead | 2 | $37 |
| UCB, Inc. | 1 | $21 |
| Amgen | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Ardelyx, Inc. | 1 | $15 |
| ERBE USA Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cologuard Collection Kit$49,561
- Skyrizi$46,655
- The Cologuard Plus Collection Kit$26,860
- Rinvoq$24,098
- COLOGUARD$16,713
- Humira$2,588
- Entyvio$1,011
- ZEPOSIA$600
- XELJANZ$242
- OCALIVA$125
- STELARA$125
- OMVOH$125
- CAPTIVATOR COLD$115
- VELSIPITY$111
How this compares
$189,776 in reported general payments places this provider in the 95th percentile of 70 gastroenterology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 40 | $1,057,273 |
| XeljanzTofacitinib Citrate | 28 | $151,375 |
| Entyvio PenVedolizumab | 13 | $133,971 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 11 | $70,409 |
| XifaxanRifaximin | 17 | $50,598 |
| Mesalamine | 40 | $23,270 |
| LinzessLinaclotide | 14 | $17,634 |
| Budesonide DrBudesonide | 26 | $5,476 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 15 | $2,421 |
| Balsalazide Disodium | 16 | $1,902 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 115 | $1,627 |
| Omeprazole | 101 | $1,539 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 83 | $1,204 |
| Famotidine | 65 | $1,048 |
| Pantoprazole Sodium | 43 | $946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $702 | $1,057,27340 claims |
| PfizerXeljanz | $17,452 | $151,37528 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $183 | $50,59817 claims |
| AbbVieLinzess | $88,085 | $17,63414 claims |
| Braintree Laboratories, Inc.Sutab | $89 | $2,42115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 70 gastroenterology providers in Idaho.
Other gastroenterology in Coeur D Alene
- Caleb KellyCoeur D Alene$7K
- Trace HeavenerCoeur D Alene$3K
- Matthew LuteCoeur D Alene$2K
- Christopher WoodCoeur D Alene$1K
- Kevin WebbCoeur D Alene$1K
- Gavin YoungCoeur D Alene$172
- Matthew SericatiBoise$111K
- Ashley EvansBoise$69K
- Bryan BrimhallBoise$10K
- Todd WilliamsIdaho Falls$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.